AbCellera Biologics Inc. (ABCL)

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Investors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL)

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera Stock Jumps 33% on a Positive Menopause Trial

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

AbCellera Biologics Q2 Earnings Call Highlights

AbCellera Reports Q2 2026 Business Results

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

Playing The Biotech Breakout With Insiders

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers